Linton, Sophia
Xu, Kayley
Hossenbaccus, Lubnaa
Botting, Hannah
Garvey, Sarah
Sunavsky, Adam
Steacy, Lisa M.
Tripp, Dean A.
Ellis, Anne K.
Funding for this research was provided by:
AstraZeneca (ESR-20-20714)
Medexus (Medexus)
Miravo (Miravo)
Reve Pharma (Reve Pharma)
Kingston Allergy Research (Kingston Allergy Research)
Article History
Received: 19 April 2023
Accepted: 6 August 2023
First Online: 23 August 2023
Declarations
:
: All participants gave their informed consent by reviewing a Letter of Information and agreeing to participate in the study. The study was reviewed for ethical compliance by the Queen’s University Health Sciences and Affiliated Teaching Hospitals Research Ethics Board.
: Not applicable.
: AKE has the following disclosures that pose no conflict of interest to the current manuscript. AKE has participated in advisory boards for ALK Abello, AstraZeneca, Aralez, Bausch Health, Circassia Ltd, GlaxoSmithKline, Johnson & Johnson, Merck, Mylan, Novartis, Pediapharm and Pfizer, has been a speaker for ALK, Aralez, AstraZeneca, Boerhinger-Ingelheim, CACME, Meda, Mylan, Merck, Novartis, Pediapharm, Pfizer, The ACADEMY, and Takeda. Her institution has received research grants from Bayer LLC, Circassia Ltd, Green Cross Pharmaceuticals, GlaxoSmithKline, Sun Pharma, Merck, Novartis, Pfizer, Regeneron and Sanofi. She has also served as an independent consultant to Allergy Therapeutics, Bayer LLC, Ora Inc. and Regeneron in the past. The authors declare that they have no competing interests.